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Background: Nephrotoxicity is the most prominent one among the various toxicities of ochratoxin A (OTA).
MicroRNAs (miRNAs) are small non-coding RNAs that have an impact on a wide range of biological processes by
regulating gene expression at post-transcriptional level or protein systhesis level. The objective of this study is to
analyze miRNA profiling in the kidneys of rats gavaged with OTA.
Results: To profile miRNAs in the kidneys of rats with OTA nephrotoxicity, high-throughput sequencing and
bioinformatics approaches were applied to analyze the miRNAs in the kidney of rats following OTA treatment.
A total of 409 known miRNAs and 8 novel miRNAs were identified in the kidney and the levels of the novel miRNAs
were varied in response to different doses of OTA. Expression of miR-129, miR-130a, miR-130b, miR-141, miR-218b
and miR-3588 were uniquely suppressed in mid dose but then elevated in high dose, with opposite expression to
their target genes. The expression pattern was closely related with the “MAPK signaling pathway”. Dicer1 and Drosha
were significantly suppressed, indicating an impairment of miRNA biogenesis in response to OTA.
Conclusions: The abrogation of miRNA maturation process suggests a new target of OTA toxicity. Moreover, the
identification of the differentially expressed miRNAs provides us a molecular insight into the nephrtoxicity of OTA.
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Ochratoxin A (OTA) is an ubiquitous mycotoxin pro-
duced by several species of Aspergillus and Penicillium
[1]. Humans are chronically and continuously exposed
to OTA because of its widespread existence in cereals
(barley, oats, rye, corn and wheat), beans, dried fruits, tea,
coffee, cocoa, wine, beer, herbs, poultry, fish, pork, eggs,
cheese and milk [2]. When consuming in excess, OTA is
known to exert a diverse range of toxicological effects
including nephrotoxicity, hepatotoxicity, teratogenicity,
mutagenicity, neurotoxicity and immunotoxicity [2,3].
It has been shown that mitogen-activated protein kin-
ase (MAPK) signaling pathway plays an important role
in mediating OTA toxicity in vivo and in vitro. MAPK
activation is proved to induce renal carcinoma in rats
chronically fed with OTA [4]. Although the link between* Correspondence: xuwentao@cau.edu.cn
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unless otherwise stated.MAPK signaling pathway and OTA toxicity has been
studied, the key miRNAs involved in the nephrotox-
icity are unknown. Understanding the linkage between
miRNAs and OTA nephrotoxicity is crucial to fill the
knowledge gap.
miRNAs are short non-coding RNAs that typically
regulate gene expression at post-transcriptional level
by binding to partially complementary sites of their
target mRNAs. A miRNA can regulate hundreds of
mRNAs and impact on crucial biological processes, in-
cluding cell growth, apoptosis, development and differ-
entiation [5]. Moreover, various miRNAs have been
established to play important roles in the development
of renal carcinoma [6-8].
The mechanism of miRNA biogenesis has become
clear. The majority of primary miRNAs (pri-miRNAs)
transcripts are generated by RNA polymerase II. Pri-
miRNAs are then cleaved into precursor miRNAs (pre-
miRNAs) by microprocessor and subsequently exported
to the cytoplasm by exportin 5 (Exp 5). The micropro-
cessors contain Drosha, a nuclear protein, and its cofactor,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DGCR8), and play a pivotal role in recognizing and
trimming pre-miRNAs. Pre-miRNAs are further cleaved
into single-stranded mature miRNAs by one of the
RNase III family enzymes – Dicer. Mature miRNAs are
then transferred to the RNA-induced silencing complex
(RISC) to mediate the degradation and/or translational
inhibition of their target RNA sequences [9]. Further-
more, the stability of miRNA biogenesis is crucial for
maintaining the cellular homeostasis. Impaired miRNA
processing has been found in various tumors [10-13],
suggesting a strong connection between miRNA pro-
cessing and cancer.
The objective of this study is to analyze miRNA profil-
ing in the kidneys of rats gavaged with OTA. The results
showed that miRNA biogenesis were impaired and that
the expression profiles of several miRNAs were altered
in association with OTA nephrotoxicity.
Results
Body and organ weights
Mean body weights were slightly reduced at 2, 3, 5, 7
and 10 (p < 0.05, data not shown) weeks after adminis-
tration of OTA at 210 μg/kg (Figure 1). Kidney weights
were significently (p < 0.05) reduced 4–26 weeks after OTA
administration (Table 1). Liver weights were increased after
OTA administration (70 μg/kg) at week 2 and decreased
(210 vs. 70 μg/kg) at week 26. OTA administration did not
impact on spleen and testis weights.
Serum clinical chemistry and histopathology
The blood clinical chemistry was not affected by OTA
doses or administration time. Blood urea nitrogen and
creatinine (BUN), common indexes of kidney damage,
did not reflect the nephrotoxicity induced by OTA. Inter-
estingly, aspartate transaminase (AST) level was higher
in the high dose than that in the mid dose group at four
weeks, but was lower in the high dose than that in the
control group at 13 weeks. The same is true for high-
density lipoprotein (HDL) and lactate dehydrogenase
(LDH) (Table 2).
In the rats administrated of OTA for 13 and 26 weeks,
cytoplasmic vacuolization was observed in the outer
stripe of outer medulla (OSOM) in both 70 μg/kg and
210 μg/kg groups. Karyomegaly (enlargement of the nu-
clei in the tubular epithelium) was prominent in tubu-
lar epithelium and the severity was OTA dose- and
time-dependent. The structure of tubular epithelium in
the rats gavaged with OTA at a dose of 210 μg/kg for
26 weeks was severely damaged. Histopathology of the
kidneys in the rats treated with OTA for 2 and 4 weeks
were generally indistinguishable. Renal lesions were not
found in the vehicle control rats (Figure 2, Additional
file 1: Figure S1).In summary, we found distinguishable (compared to
4 weeks) but not severe (compared to 26 weeks) histo-
pathological damage in groups of 13 weeks. Because
thirteen-week was a turning point where OTA started to
show its nephrotoxicity, this time point was selected for
the study of OTA nephrotoxicity and miRNA profiling
and analysis in the kidneys.
miRNA profiling
We used A, B, C and D to denote the groups of 2, 4, 13,
and 26 weeks, respectively. K (control goup), M (mid-
dose group) and H (high-dose group) represent 0, 70,
and 210 μg/kg groups, respectively. Total RNA was
pooled from rats in each group and thus three datasets
with a total of 24361780, 21752336 and 24515287 reads
were obtained from CK, CM and CH, respectively. Clean
reads (about 90% of total reads) were retained for further
analysis after removing the adapters, low quality reads
and small sequences (sizes < 18 nt) (Table 3). Analyses of
small RNA length distribution (Figure 3a) indicated that
the three samples peaked at the size of 22 nt, suggesting
the homogeneity of the samples. CK and CH were al-
most superimposed. Next, clean reads were compared
with the Rfam database (ftp://selab.janelia.org/pub/Rfam)
to match with the known rRNA, snRNA, snoRNA and
tRNAsequences (Figure 3b – d). After these non-coding
RNAs (ncRNAs) were removed, the remaining clean
reads were further compared with the pre-miRNAs data-
base in miRbase. The matched reads were used to iden-
tify mature miRNAs, and the number of their reads were
accounted. The reads that did not yield a match were
used to predict novel miRNAs using MIREAP. The num-
bers of miRNA reads were normalized by Tags per million
(TPM) values (TPM = (miRNA total reads/total clean
reads) × 106) to express miRNAs in CK, CM, CH comapr-
able in one table.
Novel miRNA analysis
A number of criterions were used for evaluating whether
a small RNA was a genuine miRNA, such as formation
of a stable hairpin structure, lower minimal free energies
for hairpin structure of its precursors, and detection of
miRNA*s [14]. Given these analyses, 8 novel miRNAs
were identified and examined by PCR (Additional file 1:
Table S1, Additional file 1: Figure S2, Figure 4).
Impairment of miRNA processing
A total of 409 known miRNAs were found in CK, CM, and
CH kidneys, 394 of which were differentially (p <0.05)
expressed among the three groups (Additional file 1:
Table S2). We further mapped the distribution of the
miRNA length (Additional file 1: Figure S3), which was
consistent with the pattern shown in Figure 3a. Total
miRNAs in CM was slightly lower than those in CH and
Figure 1 Body weight of the male rats after OTA administration at the indicated doses.
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analysis depicted that miRNA expression was similar be-
tween CK and CH, and they were different from CM kid-
neys (Figure 5). Therefore, differences of the expression
pattern in the three groups are likely due to the impair-
ment of miRNA processing after OTA nephrotoxicity.
To further understand the nature of the defective
miRNA processing after OTA toxicity, we determined
the expression of key regulators of miRNA processing:
Drosha, Dicer1 and DRCG8. As shown in Figure 6, mRNA
levels of Drosha and Dicer1, but not DRCG8, were signifi-
cantly reduced after OTA administrtaion.
Analysis of known miRNA expression pattern
Expression pattern of all known miRNAs was exam-
ined by using STEM software. Two significant profiles(profile 1 and 5) containing 77 miRNAs were identified
(Figure 7). Expression of these 77 miRNAs in both pro-
files were repressed in CM and reversed in CH kidneys.
Among these 77 miRNAs, those with ≥ 2-fold down-
regulation in CM compared to CK (miR-129, miR-130a,
miR-130b, miR-141, miR-218b and miR-3588) were se-
lected for bioinformatic analysis.
The information on the putative target genes of these
6 miRNAs were collected using the comparative plat-
form of miRWalk [15] by considering six different al-
gorithms, including miRanda, miRDB, miRWalk, PITA,
TargetScan and RNAhybrid. Demanding a target gene
to be predicted by different miRNA-target prediction
algorithms can be helpful in minimizing the number of
putative and maybe false positive targets [16-18]. There-
fore, the targets predicted with at least 2 different programs
Table 1 Organ weights after administration of OTA (0, 70, 210 μg/kg body weight) for 2, 4, 13 and 26 weeks
Time (weeks) Dose (μg/kg) Liver (g) Kidney (g) Spleen (g) Testicle (g)
2 0 5.59 ± 0.44 1.40 ± 0.12 0.46 ± 0.02 2.28 ± 0.09
70 6.35 ± 0.43 a 1.56 ± 0.09 a 0.44 ± 0.04 2.37 ± 0.20
210 5.83 ± 0.75 1.40 ± 0.11 b 0.43 ± 0.06 2.49 ± 0.35
4 0 6.19 ± 0.80 1.57 ± 0.14 0.45 ± 0.04 2.55 ± 0.12
70 6.18 ± 1.33 1.57 ± 0.21 0.46 ± 0.07 2.56 ± 0.28
210 5.98 ± 0.79 1.43 ± 0.12 0.43 ± 0.04 2.63 ± 0.07
13 0 8.06 ± 1.43 2.03 ± 0.10 0.56 ± 0.79 2.93 ± 0.06
70 6.84 ± 0.68 1.83 ± 0.12 a 0.54 ± 0.05 3.00 ± 0.20
210 6.86 ± 0.70 1.51 ± 0.74 ab 0.50 ± 0.46 2.83 ± 0.17
26 0 7.48 ± 0.72 2.02 ± 0.24 0.54 ± 0.06 3.13 ± 0.25
70 8.11 ± 0.96 2.04 ± 0.14 0.58 ± 0.06 3.20 ± 0.11
210 6.72 ± 0.68 b 1.67 ± 0.19 ab 0.54 ± 0.07 3.10 ± 0.16
a: p < 0.05, compared to 0 μg/kg b.w. group; b: p < 0.05, compared to 70 μg/kg b.w. group.
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and collective KEGG/GO enrichment analysis were
performed. In separative analysis, the predicted target
genes were subjected to KEGG/GO enrichment ana-
lysis individually, following by a multiple testing method
(Benjamini and holm, BH) to select for significantly
(p < 0.05) over-represented KEGG pathways and GOBPs
(Table 4A and B, full tables are given in Additional
file 1: Table S3). In collective analysis, the identified
targets were merged into one list, and non-redundant
genes were removed followed to carry out KEGG/GO
enrichment analysis (Additional file 1: Table S4 A
and B). “phosphatidylinositol signaling system”, “pancre-
atic cancer” and “MAPK signaling pathway” were greatly
enriched as evidenced by both separative and collective
analyses. Notably, regulation of the pathways and GOBPs
were strongly associated with miR-129, miR-130a and
miR-130b. No relevant pathways and GOBPs were found















2 0 45.17 ± 5.04 283 ± 63 52.4 ± 0.9 310 ± 31 3.37
70 45.2 ± 6.30 241 ± 53 51.7 ± 2.9 315 ± 33 4.71
210 42.67 ± 6.44 208 ± 448 50.1 ± 2.1 305 ± 41 4.3 ±
4 0 50.00 ± 3.08 240 ± 25 75.0 ± 3.5 288 ± 36 4.99
70 52.83 ± 6.79 225 ± 61 76.5 ± 4.2 367 ± 78a 5.76
210 52.33 ± 5.39 305 ± 61b 72.4 ± 2.7 275 ± 14b 3.71
13 0 56.50 ± 7.61 167 ± 17 49.2 ± 1.5 152 ± 17 7.91
70 52.17 ± 2.99 152 ± 7 51.1 ± 2.4 153 ± 10 7.34
210 52.33 ± 4.23 140 ± 13a 51.2 ± 2.4a 157 ± 11 7.76
Data are presented as Mean ± SD of six rats per group. a: p < 0.05 when compared tobe explained by the less putative targets prediction of the
two miRNAs.
Differently expressed miRNAs
We further analyzed the differentially expressed miRNAs
in CH group (Table 5A). There were 10 up-regulated
and 23 down-regulated miRNAs with ≥ 3-fold difference
(p <0.05).
Putative target mRNAs of 31 miRNAs were predicted
as previously mentioned (rno-mir-378b and mir-1843-5p
are not found in the selected databases). Thereafter,
separative and collective KEGG/GOBPs analyses were
accomplished as a result of meta-analysis predictions
(BH < 0.05). In separative analysis, seventy-eight path-
ways were enriched in the “10 up-regulated” and ninety-
three were enriched in the “21 down-regulated” miRNAs,
while 208 and 230 GOBPs were enriched in the “10 up-
regulated” and “21 down-regulated” miRNAs, respectively












± 1.61 6.2 ± 0.5 37 ± 16 2.52 ± 0.31 0.59 ± 0.17 3484 ± 696
± 1.07 6.2 ± 0.4 29 ± 2 2.91 ± 0.46 0.96 ± 0.42 3062 ± 632
1.03 6.2 ± 0.7 31 ± 10 2.37 ± 0.23 0.72 ± 0.18 2644 ± 506a
± 1.1 5.7 ± 0.7 28 ± 3 2.96 ± 0.34 0.64 ± 0.2 3370 ± 338
± 1.04 6.7 ± 0.8 32 ± 7 2.89 ± 0.47 0.82 ± 0.14 2965 ± 769
± 1.12b 6.1 ± 0.9 34 ± 4 3.42 ± 0.18b 0.83 ± 0.22 3842 ± 727b
± 1.02 8.5 ± 0.5 43 ± 2 3.42 ± 0.55 0.77 ± 0.16 2043 ± 237
± 0.63 8.7 ± 0.5 43 ± 4 2.93 ± 0.25 0.69 ± 0.09 1974 ± 153
± 0.99 8.5 ± 0.5 43 ± 9 2.69 ± 0.13a 0.74 ± 0.15 1763 ± 208a
0 μg/kg b.w. group; b: p < 0.05 when compared to 70 μg/kg body weight group.







CK Total reads number 24361780 100%
Low quality 18020 0.07%
Adaptor3 null 1258473 5.17%
Insert null 0 0%
5′ adaptor contaminants 7165 0.03%
small.txt, size < 18 nt 1107061 4.54%
polyA 4660 0.02%
High Quality (size≥ 18 nt) 21966401 90.17%
CM Total reads number 21752336 100%
Low quality 15999 0.07%
Adaptor3 null 1838914 8.45%
Insert null 0 0%
5′ adaptor contaminants 4953 0.02%
small.txt, size < 18 nt 756277 3.48%
polyA 4045 0.02%
High Quality (size≥ 18 nt) 19132148 87.95%
CH Total reads number 24515287 100%
Low quality 20684 0.08%
Adaptor3 null 1179046 4.81%
Insert null 0 0%
5′ adaptor contaminants 5293 0.02%
small.txt, size < 18 nt 865014 3.53%
polyA 3918 0.02%
High Quality (size≥ 18 nt) 22441332 91.54%
Figure 2 H & E stained kidney sections of a control rat (a) and
of rats treated with 70 (b) and 210 (c) μg/kg b.w. OTA for
13 weeks. At 70 and 210 μg/kg b.w., OTA induced severe
cytoplasmic vacuolization (thin arrow) and karyomegaly (thick
arrow) in proximal tubular epithelial cells in outer stripe of outer
medulla (OSOM).
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(Figures 8a and b). Interestingly, the majority of the 63
pathways were overlapped between the “10 up-regulated”
and “21 down-regulated” miRNAs. Similarly, a total of 197
GOBPs were commonly identified between the two groups
of miRNAs.Twenty-five miRNAs that were deregulated in the
CM group (10 were up-regulated and 15 were down-
regulated, 3-fold difference, p < 0.05) were also sub-
jected to KEGG/GO enrichment analysis (Additional
file 1: Table S6 B). miR-3473 was not found in the se-
lected database. In separative analysis, 73 and 95 path-
ways and 219 and 220 GOBPs were over-represented in
the “9 up-regulated” and “15 down-regulated” miRNAs,
respectively. Moreover, extensive overlaps were noted be-
tween pathways and GOBPs (Figures 8c and d). The tar-
get genes involved in these pathways or GOBPs were
given in Additional file 1: Tables S6 A-D.
PCR validation for Nrf2, Keap1 and miRNAs
We tested the gene expression of Nrf2 and its negative
regulator, Keap1. Nrf2 mRNA level in the kidney was
significantly decreased (p < 0.05) after OTA treatment
(210 μg/kg), and the expression of Keap1 was significantly
increased by OTA treatment (Figure 9).
Among the six miRNAs that selected by STEM ana-
lysis, 4 miRNAs (most of the pathways were enriched by
Figure 3 RNA length and types distribution in CK, CM and CH. (a) Length distribution of small RNA reads percentage in CK, CM and CH. The
distribution of RNA types in CK (b), CM (c) and CH (d) were summarized. CK, group of rats gavaging 0 μg/kg OTA for 13 weeks; CM, group of rats
gavaging 70 μg/kg OTA for 13 weeks; CH, group of rats gavaging 210 μg/kg OTA for 13 weeks.
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over, miR-141 is valuable in disscussion part) were
analyzed by qRT-PCR to validate the results of high
throughput sequencing data. In agreement with sequen-
cing data, miR-129, miR-130b and miR-141 were down-
regulated in CM and up-regulated in CH, although no
signicance was found in miR-141. No change was found
in miR-130b according to qRT-PCR (Figure 10b).
The expression of miR-129, miR-130a, miR-130b and
miR-141 was also examined in kidneys of rats in groups
of 4 weeks and 26 weeks. Both of miR-130b and miR-
141 were up-regulated after administrated with OTA for
4 weeks (Figure 10a). In the 26-week group, the expres-
sion of miR-129 and miR-130b were decreased, while
miR-141 was increased (Figure 10c). There was no sig-
nificant effect of OTA on the expression of miR-130a.
Primers used in the qRT-PCR were listed in Additional
file 1: Table S7.Figure 4 The validation of 8 identified novel miRNAs in the
kidney by PCR. The two left lanes indicated miRNAs and the right
depicts the negative control.qRT-PCR validation of the miRNA targets
The mRNA expression of Smoc2/Dcn (miR-129), Emp1/
Rapgef5 (miR-218b), lgfbp3/sepp1 (miR-141), lgfbp3/
Sepp1/Col1a2/Edem1 (miR-130a/miR-130b) and Edem1/
Dpt (miR-3588) at 13 weeks are strongly correlated with
its corresponding miRNAs shown in the parentheses.
Smoc2/Dcn, lgfbp3/sepp1, lgfbp3/Sepp1/Col1a2/Edem1
and Edem1/Dpt mRNA levels were increased signifi-
cantly in CM compared to CK group. Emp1/Rapgef5
mRNA levels were increased in both CM and CH groups
(Additional file 1: Figure S4). All the primers used in the
qRT-PCR analyses were listed in Additional file 1:
Table S8. The expression trendency of these mRNA tar-
gets is opposite to the expression of their correspond-
ing miRNAs as shown in the profiling data.
Dcn mRNA, a target gene of miR-129, encodes a pro-
tein that regulates cell cycle. Furthermore, a surfeit in
Dcn expression exists in diabetic renal damage. Dcn
mRNA levels in the kidney of streptozotocin-induced
diabetes in mice are rapidly elevated following the in-
duction of diabetes [19]. Sepp1, a target of miR-141, is a
major extracellular selenoprotein that is synthesized and
secreted from the kidneys and plays critical roles in body
selenium homeostasis.
Discussion
The integrity of miRNA processing machanism plays a
pivotal role in homeostasis and the regulation of various
Figure 5 Hierachical clustering for the differentially expressed
miRNAs. The color scale illustrates the relative expression level of
the identified miRNAs across the three samples. The blue denotes
expression < 0 and the green denotes expression > 0. The euclidean
distance measure was used to calculate the distance. The CK, CM
and CH groups, rats gavaging 0, 70, and 210 μg/kg OTA, respectively,
for 13 weeks.
Figure 6 qRT-PCR analyses of Drosha, DRCG8 and Dicer1 mRNA
levels in the kidneys of the rats in CK, CM and CH. Expression
levels were normalized using β-actin. Values are mean ± s.d. (n = 6).
***, p < 0.01.
Dai et al. BMC Genomics 2014, 15:333 Page 7 of 14
http://www.biomedcentral.com/1471-2164/15/333diseases. Origins of various forms of cancer including
ovarian, lung, gastric and breast are accompanied with
decreased expression of Dicer and Drosha [10-13]. More-
over, abrogation of Drosha, DRCG8 or Dicer substantially
increases the possibility of cellular transformation and
tumorigenesis [20]. The observation that Drosha (~2-fold)
and Dicer1 (~5-fold) were down-regulated in the kidneys
of rats after OTA administration suggests that dysregula-
tion of miRNA processing may attribute to OTA nephro-
toxicity and renal carcinogenesis.
How miRNA processing might be associated with OTA-
induced renal toxicity and carcinogenesis? It is known that
Dicer can stimulate p-Akt, PCNA [21] and c-Myc [20]Figure 7 The expression pattern of miRNAs in response to
various doses of OTA. Two significant profiles (profile 1 and profile 5)
out of 16 profiles were detected as significant using STEM analysis. Red
lines represent individual miRNA whose expression correlates with OTA
doses. Black curve represents the model of the profile to which the
miRNA expression pattern are similar. The numbers in the upper and
lower left corners are the identifier (ID) of the profile and the number of
miRNAs in a that profile.

















rno04070 Phosphatidylinositol signaling system 4 1 1 1 0 1 0
rno05212 Pancreatic cancer 3 1 1 1 0 0 0
rno04971 Gastric acid secretion 3 1 1 1 0 0 0
rno04010 MAPK signaling pathway 3 1 1 1 0 0 0
rno04622 RIG-I-like receptor signaling pathway 3 1 1 1 0 0 0
rno00380 Tryptophan metabolism 3 1 1 1 0 0 0
rno04730 Long-term depression 3 1 1 1 0 0 0
rno00410 beta-Alanine metabolism 3 1 1 1 0 0 0
rno04110 Cell cycle 3 1 1 1 0 0 0
rno04114 Oocyte meiosis 3 1 1 1 0 0 0
…
rno05410 Hypertrophic cardiomyopathy (HCM) 1 1 0 0 0 0 0
Total pathways targeted by each miRNA 47 48 47 0 1 0
B
GO:0016043 ~ cellular component organization and biogenesis 5 1 1 1 1 0 1
GO:0050789 ~ regulation of biological process 5 1 1 1 1 0 1
GO:0008283 ~ cell proliferation 5 1 1 1 1 0 1
GO:0065007 ~ biological regulation 5 1 1 1 1 0 1
GO:0048519 ~ negative regulation of biological process 5 1 1 1 1 0 1
GO:0006796 ~ phosphate metabolic process 4 1 1 1 0 0 1
GO:0030154 ~ cell differentiation 4 1 1 1 0 0 1
GO:0008104 ~ protein localization 4 1 1 1 0 0 1
GO:0051336 ~ regulation of hydrolase activity 4 1 1 1 0 0 1
GO:0051179 ~ localization 4 1 1 1 0 0 1
…
GO:0043434 ~ response to peptide hormone stimulus 1 1 0 0 0 0 0
Different pathways predicted by each miRNA 162 157 156 5 0 27
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liferation and invasion in tumor cells. On the other hand,
Akt1, c-Myc [22] and PCNA [23], proteins associated with
cell survival and proliferation, are up-regulated in the
kidney after OTA exposure. This suggests that Dicer
might mediate the carcinogenicity of OTA by regulating
Akt, c-Myc and PCNA. Dicer is also required for the
maturation of short interfering RNAs (siRNAs) [24,25],
which specifically degrade their target mRNAs. Thus,
OTA-induced down-regulation of Dicer might also dis-
turb the RNA interfering (RNAi) system. Decreased ex-
pression of Dicer (both in the CM and CH groups) and
Drosha (only in the CH group) in kidneys may position
the OTA-gavaged rats at an extremely complex toxi-
cological response, which might include the inhibition
of both miRNA and siRNA. DRCG8 is the only knownprotein that is specific to the miRNA processing path-
way [26]. Because the expression of DRCG8 is not af-
fected by OTA administration, we speculate that an
organism or a cell could initiate other regulatory path-
ways for the maturation or compensation of endogenous
miRNAs, when down-regulation of global expression of
miRNAs occurs due to a severe impairment in the clas-
sical miRNA processing pathway. Thus, further investiga-
tions are needed to better understand OTA-induced
inhibitory mechanism of miRNA biogenesis.
Results from hierachical clustering analyses demon-
strate that CK and CH groups are closer in euclidean
distance. Interestingly, hierachical clustering analysis of
the gene expression in rats fed with OTA for less than
12 months indicates that a cluster was noted between
the early (7 days) and the late responses (12 months)
Table 5 Deferentially expressed miRNAs in CH (A) or CM (B)
A B
Mature miRNA Fold change P-vaule Mature miRNA Fold change P-value
Up-regulated miRNAs rno-miR-3065-3p 21.0 <0.0001 rno-miR-3556a 85.0 <0.0001
rno-miR-653 17.0 <0.0001 rno-miR-653 20.3 <0.0001
rno-miR-3596b 15.4 <0.0001 rno-miR-3596b 10.8 <0.0001
rno-miR-3556b 10.1 <0.0001 rno-miR-30c 4.8 <0.0001
rno-miR-504 8.4 <0.0001 rno-miR-145 4.2 <0.0001
rno-miR-3596a 8.3 <0.0001 rno-miR-19a 4.1 <0.0001
rno-miR-3596c 8.3 <0.0001 rno-miR-19b 4.1 <0.0001
rno-miR-30c 4.3 <0.0001 rno-miR-3590-5p 4.0 <0.0001
rno-miR-338 4.2 0.000126 rno-miR-3473 3.0 <0.0001
rno-miR-200c 3.7 0.006459 rno-miR-338 3.0 0.001122
Down-regulated miRNAs rno-miR-133a −28.6 <0.0001 rno-miR-218b −98.6 <0.0001
rno-miR-133b −28.6 <0.0001 rno-miR-130a −63.9 <0.0001
rno-miR-128 −13.7 <0.0001 rno-miR-130b −63.9 <0.0001
rno-miR-182 −13.3 <0.0001 rno-miR-3588 −31.3 <0.0001
rno-miR-190* −10.6 <0.0001 rno-miR-129 −24.2 <0.0001
rno-miR-3587 −9.8 <0.0001 rno-miR-138 −11.5 <0.0001
rno-miR-135a −9.2 <0.0001 rno-miR-182 −11.3 0.000154
rno-miR-135b −9.2 <0.0001 rno-miR-133a −6.7 <0.0001
rno-miR-186 −8.7 <0.0001 rno-miR-133b −6.7 <0.0001
rno-miR-2964 −6.6 0.003196 rno-miR-136* −5.7 0.022282
rno-miR-96 −6.6 0.003196 rno-miR-141 −5.6 <0.0001
rno-miR-378b −5.7 <0.0001 rno-miR-3596c −5.1 <0.0001
rno-miR-378 −5.7 <0.0001 rno-miR-3596d −5.1 <0.0001
rno-miR-328b-3p −4.4 0.009016 rno-miR-9b-5p −4.8 0.005151









“*”represents that a mature microRNA is expressed from both the 5'-arm and the 3'-arm.
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http://www.biomedcentral.com/1471-2164/15/333[22]. These results suggest that OTA may mediate
nephrotoxicity in an age-dependent manner. The hierachi-
cal clusterings, small RNA and miRNA length distribution
pattern suggest that a series of signaling pathways are af-
fected and orchestrated at the early response to OTA tox-
icity and that the transition period might be of paramount
importance in the regulation of nephrotoxicity.
Based on the expression pattern, miRNA expression was
decreased in CM and increased in CH, which was consist-
ent with results from our hierachical clusterings. KEGGand GO enrichment analyses were further performed in
the six differentially expressed miRNAs (miR-129, miR-
130a, miR-130b, miR-141, miR-218b and miR-3588),
demonstrating that “phosphatidylinositol signaling sys-
tem”, “pancreatic cancer” and “MAPK signaling path-
way” were mostly significantly enriched. Specifically,
several previous studies addressed the involvement of
MAPK pathway in the development of OTA-induced tox-
icity [4,22,27,28]. After the male rats were fed with OTA
at a concentration of 300 μg/kg for 12 months, the
Figure 8 Venn diagrams for the overlapping KEGG pathways (a and c) or GOBP analyses (b and d) in up- or down-regualted miRNAs in
CH (a and b) or CM (c and d) groups.
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http://www.biomedcentral.com/1471-2164/15/333kidneys were used to analyse key players in the MAPK
pathway [4]. OTA administration induces the phosphor-
ylation of PKCζ. One of its selective downstream target,
ERK 1/2, was markedly increased at day 7. The up-
stream mediator of PKC phosphorylation, PKD, is
also activated by phosphoprotein at day 7. Substrates
of ERK 1/2, ELK 1/2 and p90RSK are also signifi-
cantly activated at days 7 and 21. The expression of
insulin-like growth factor 1 receptor (IGF-1r), an up-
stream molecule of PDK1, is increased at day 7 and 21,
followed by a decline after 12 months of treatment. The
aforementioned signals typically lead to cell proliferation.
Analyses of the MAPK pathway have helped to confirmFigure 9 qRT-PCR analyses of Nrf2 and Keap1 mRNA levels in
the kidneys of the rats in CK, CM and CH groups. Expression
levels were normalized by β-actin. Values are mean ± s.d. *, p < 0.05.that this pathway is critical in the kidneys of rats after
OTA administration. After a long-term gavaging,
MAPK pathway tends to be progressively repressed.
Nonetheless, further transcriptomic and proteomic
analyses are needed to provide a full spectrum of the
OTA-induced gene expression changes.
Interestingly, our results showed that OTA induced
up-expression of miR-130b in the 4 and 13 weeks
groups, then a down-expression in the 26 weeks groups,
indicating the different effect of OTA on miR-130b be-
tween the short- and long-term treatment.
Overexpression of miR-133b in HeLa cells increases
tumor necrosis factor-α-induced cell death [29]. Co-
incidently, OTA exacerbates renal cell proliferation,
extending from the medullary rays into the OSOM
in a dose- and time-dependent manner [30]. Down-
regulation of miR-133b in the CH group implies an
undermined programmed cell death mechanism in the
kidney and offers a possible explanation of renal cell pro-
liferation stimulated by OTA. Transgelin 2 (TAGLN2), an
inhibitior of cell proliferation in renal carcinoma (RCC),
is an intriguing target of miR-133a. TAGLN2 is recog-
nized as an oncogene and diminished expression of miR-
133a is frequently shown in RCC [31]. Similar result is
shown in bladder cancer cell lines [32]. Moreover, miR-
133b reduces the expression of glutathione-S-transferase
pi (GSTP, encode by Gstp1 in human), one of the phase
II enzymes involved in xenobiotic metabolism. After
throughly scrutinizing a transcriptomics result from
kidneys of rats after 2 years of daily dietary intake of OTA,
Figure 10 qRT-PCR analysis of miR-129, miR-130a, miR-130b
and miR-141 expression in the kidneys of the rats in 4 weeks
(BK, BM and BHgroups, Figure 10a), 13 weeks (CK, CM and CH
groups, Figure 10b) and 26 weeks (DK, DM and DH groups,
Figure 10c). Expression levels were normalized by 5S. Values were
mean ± s.d. a: p < 0.05 when compared to 0 μg/kg b.w. group;
b: p < 0.05 when compared to 70 μg/kg body weight group.
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http://www.biomedcentral.com/1471-2164/15/333we have previously shown that expression of GSTP
(encode by Gstp2 in rat) is impaired [22]. This reveals a
possible linkage between miR-133b and GSTP in mediating
OTA toxicity.
OTA increases miR-132 and miR-200c expression in
porcine renal proximal tubular cells [33]. The induction
of these two miRNAs may attenuate the expression of
Nrf2 and HO-1, resulting in the elevation of ROS level
and the expression of the profibrotic TGFβ. Future in vivo
studies are needed to verify the link between Nrf2 and
miRNA following OTA toxicology.Keap1 is a negative regulator of Nrf2 [34,35]. We have
herein found that Nrf2 expression was significantly de-
creased as OTA doses increased. A previous study has
demonstrated that OTA induces the disruption of Nrf2
expression and its corresponding downstream proteins
[22]. This has been proved to be associated with an in-
hibition of Nrf2 binding to the antioxidant responsive
element at the promoter region in vitro [36]. According
to our results, down-regulation of Nrf2 might be due to
the elevated Keap1 expression. However, since OTA
treatment induces miRNA-141, a regulator of Keap1 [37],
in 2 and 26 weeks after OTA adminstration, it seems im-
possible that an elevation in the expression of Keap1 is due
to down-regulation of miRNA-141.
Conclusions
A high-throughput sequencing approach has been used
to explore the differentially expressed miRNAs in the
kidneys of rats in response to different doses of OTA.
MAPK signaling pathway may play a vital role in mediat-
ing OTA toxicity. KEGG and GO enrichment analyses
have been performed and the results are consistent with
the previous OTA studies. Most importantly, we have
shown herein that the miRNA processing machanism
is severely hampered by OTA treatment. The differ-
entially expressed miRNAs after OTA administration
have been analyzed and validated, most of which are
in agreement with the sequencing results. These findings
provide the first and valuable information for exploring




Male F344 rats (6–7 weeks old) were purchased from
Vitalriver, Beijing, China. Animals were housed in a
stainless steel (three rats/cage) with ad libitum access
to filtered tap water and commercial feed in a specific
pathogen free (SPF) animal room of The Supervision
and Testing Center for GMOs food safety, Ministry of
Agriculture (Beijing, China). All experimental procedures
involving animals were approved (permission number:
120020) by the Ethics Committee of China Agricultural
University.
Study design
After a week of acclimatization, rats (six per group) were
administered with OTA at doses of 0, 70 or 210 μg/kg
body weight in corn oil (Aladin, Shanghai, China) by gav-
age for 2, 4, 13 or 26 weeks (5 days per week) [38]. Rats
were anesthetized using chloral hydrate (6%, 5 ml/kg, ip)
and decapitated. The Kidneys and the livers were weighted,
snap-frozen immediately in liquid nitrogen, and stored
at −80°C until further analysis.
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The serum biochemical parameters were measured
using a Hitachi 7020 automatic biochemical analyzer
(Hitachi, Tokyo, Japan). They include ALT, alanine ami-
notransferase; AST, aspartate transaminase; ALB, al-
bumin; ALP, alkaline phosphatase; GLU, glucose; BUN,
blood urea nitrogen; CREA, creatinine; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; LDH, lactate
dehydrogenas.
Pathology
Samples from the kidneys and the livers were fixed in
4% buffered formaldehyde and embedded in paraffin.
The tissue sections (5 μm thick) were affixed to slides
and stained with haematoxylin and eosin (H & E) for
microscopic examination. Histopathological examination
of tissue sections was conducted at the Experimental
Animal Research Center, China Agricultural University.
miRNA library construction and sequencing procedures
Total RNA was extracted from the kidneys using mir-
Vana™ miRNA isolation kit (Ambion, USA) following the
manufacturer’s instruction. The quality of the purified
RNA was assessed using a BioAnalyzer 2100 (Agilent
Technology, Santa Clara, USA) with the parameters:
RIN ≥ 7.5, concentration ≥ 200 ng/μl. RNA samples were
stored at −80°C and were sequenced with the Solexa/
Illumina platform.
For small RNA library construction and deep se-
quencing, small RNA was enriched by PEG8000 pre-
cipitation from 10 μg of total RNA, followed by DNA
sequencing with an Illumina Hiseq 2000 (Illumina, San
Diego, USA) according to manufacturer’s instruction.
Briefly, proprietary adapters were ligated to the 5′ and
3′ termini of these small RNAs, of which the ligated
small RNAs were then used as templates for cDNA
synthesis. The cDNA was amplified with 15 PCR cy-
cles to generate cDNA libraries. The libraries were
quantified by ECO (Illumina, San Diego, USA) and se-
quenced using the Solexa’s proprietary sequencing-
by-synthesis method. The image files generated by the
sequencer were then processed to produce digital quality
data. After masking of adaptor sequences and removal of
contaminated reads, full-length small RNA sequences
were selected for further analysis. For quality control, we
calculated the average quality score of sites and reads of
each sample.
qRT-PCR
Quantitative real-time PCR (qRT-PCR) was performed
on 200 ng of total RNA extracts that had been poly-
adenylated and reverse transcribed into cDNA using
an anchored oligo(dT) primer (Tiangen, Beijing, China).
The miRNA was transcribed into first-strand cDNAusing miRcute miRNA first-strand cDNA synthesis kit
miRNA (Tiangen, Beijing, China). PCRs were run using
the miRcute miRNA qPCR detection kit (Tiangen,
Beijing, China). The miRNA primers were designed ac-
cording to the instrution.
mRNA was transcribed into first-strand cDNA using
Quantscript RT Kit (Tiangen, Beijing, China). qRT-
PCR was run using the RealMasterMix (SYBR green I)
(Tiangen, Beijing, China) with β-actin being the internal
control. The genes include Drosha, DRCG8, Dicer1, Nrf2,
Keap1 and the target genes of some miRNAs. qRT-PCRs
were run on the ABI 7500 Real-time PCR machine
(Applied Biosystems, Foster City, USA). Data were ana-
lyzed using the delta–delta–Ct method.
Statistics
Serum clinical chemistry and body weight are expressed
as mean ± SD of six individual animals, while miRNA
and mRNA are expressed as mean ± SD of four individ-
ual animals. Statistical analyses were performed using
one-way ANOVA followed by LSD test. A p value < 0.05
was considered statistically significant.
Availability of supporting data
All sequencing data are available through ArrayExpress.
Accession number: E-MTAB-2475.
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